Verrica Pharmaceuticals (VRCA) Short Interest Ratio & Short Volume → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free VRCA Stock Alerts $7.84 +0.23 (+3.02%) (As of 05/9/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Verrica Pharmaceuticals Short Interest DataCurrent Short Volume3,840,000 sharesPrevious Short Volume4,180,000 sharesChange Vs. Previous Month-8.13%Dollar Volume Sold Short$26.57 millionShort Interest Ratio / Days to Cover28.3Last Record DateApril 15, 2024Outstanding Shares42,420,000 sharesFloat Size25,450,000 sharesShort Percent of Float15.09%Today's Trading Volume106,916 sharesAverage Trading Volume166,209 sharesToday's Volume Vs. Average64% Short Selling Verrica Pharmaceuticals ? Sign up to receive the latest short interest report for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatVRCA Short Interest Over TimeVRCA Days to Cover Over TimeVRCA Percentage of Float Shorted Over Time Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide Verrica Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20243,840,000 shares $26.57 million -8.1%15.1%28.3 $6.92 3/31/20244,180,000 shares $24.75 million -5.0%16.5%28.2 $5.92 3/15/20244,400,000 shares $21.12 million -0.7%17.4%22.4 $4.80 2/29/20244,430,000 shares $23.35 million +1.1%17.4%4.1 $5.27 2/15/20244,380,000 shares $24.35 million -1.1%17.3%4.1 $5.56 1/31/20244,430,000 shares $25.03 million -20.2%17.7%4.1 $5.65 Get the Latest News and Ratings for VRCA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/20245,550,000 shares $31.75 million +5.3%22.1%5.1 $5.72 12/31/20235,270,000 shares $38.58 million +44.4%21.0%4.9 $7.32 12/15/20233,650,000 shares $22.23 million -8.5%14.6%3.4 $6.09 11/30/20233,990,000 shares $14.68 million -6.3%15.9%25 $3.68 11/15/20234,260,000 shares $13.50 million +1.2%17.0%23.9 $3.17 10/31/20234,210,000 shares $15.49 million -2.3%16.7%21.7 $3.68 10/15/20234,310,000 shares $15.73 million -3.8%17.1%15.1 $3.65 9/30/20234,480,000 shares $17.40 million -9.3%17.8%11.8 $3.89 9/15/20234,940,000 shares $20.01 million +1.9%19.6%12.6 $4.05 8/31/20234,850,000 shares $22.07 million +7.5%19.3%11.5 $4.55 8/15/20234,510,000 shares $22.50 million +11.1%17.8%11.1 $4.99 7/31/20234,060,000 shares $23.71 million +34.4%16.0%10.7 $5.84 7/15/20233,020,000 shares $20.20 million +3.8%12.0%9.4 $6.69 6/30/20232,910,000 shares $16.79 million +33.5%11.5%13.3 $5.77 6/15/20232,180,000 shares $13.67 million +6.9%8.6%10.6 $6.27 5/31/20232,040,000 shares $11.57 million +14.6%8.1%13.4 $5.67 5/15/20231,780,000 shares $10.86 million +21.1%7.1%10.9 $6.10 4/30/20231,470,000 shares $9.07 million +55.7%5.9%7.6 $6.17 4/15/2023944,100 shares $5.85 million +60.7%3.8%4.9 $6.20 3/31/2023587,500 shares $3.82 million +94.8%2.4%3 $6.50 3/15/2023301,600 shares $2.01 million +24.8%1.2%1.7 $6.65 2/28/2023241,600 shares $1.87 million -7.5%1.0%1.4 $7.75 2/15/2023261,200 shares $1.97 million +12.1%1.1%1.6 $7.54 1/31/2023233,000 shares $1.08 million -50.7%1.0%1.7 $4.62 1/15/2023472,500 shares $2.29 million -18.4%2.0%4.2 $4.85 12/30/2022579,300 shares $1.59 million -7.9%2.4%5.9 $2.75 12/15/2022629,000 shares $1.98 million -4.2%2.6%8.1 $3.14 11/30/2022656,300 shares $2.13 million -5.7%2.7%6.6 $3.25 11/15/2022695,800 shares $1.59 million +6.0%2.9%7.1 $2.28 10/31/2022656,300 shares $1.63 million +7.0%2.7%6.5 $2.49 10/15/2022613,200 shares $1.67 million -1.9%2.6%5.7 $2.73 9/30/2022625,100 shares $1.83 million -19.6%2.6%4.5 $2.92 9/15/2022777,900 shares $2.96 million -9.8%3.2%2.4 $3.80 8/31/2022862,400 shares $3.38 million -10.1%3.7%2.6 $3.92The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide VRCA Short Interest - Frequently Asked Questions What is Verrica Pharmaceuticals' current short interest? Short interest is the volume of Verrica Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 3,840,000 shares of VRCA short. 15.09% of Verrica Pharmaceuticals' shares are currently sold short. Learn More on Verrica Pharmaceuticals' current short interest. What is a good short interest ratio for Verrica Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VRCA shares currently have a short interest ratio of 28.0. Learn More on Verrica Pharmaceuticals's short interest ratio. What is a good short interest percentage for Verrica Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 15.09% of Verrica Pharmaceuticals' floating shares are currently sold short. Is Verrica Pharmaceuticals' short interest increasing or decreasing? Verrica Pharmaceuticals saw a decline in short interest in April. As of April 15th, there was short interest totaling 3,840,000 shares, a decline of 8.1% from the previous total of 4,180,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Verrica Pharmaceuticals' float size? Verrica Pharmaceuticals currently has issued a total of 42,420,000 shares. Some of Verrica Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Verrica Pharmaceuticals currently has a public float of 25,450,000 shares. How does Verrica Pharmaceuticals' short interest compare to its competitors? 15.09% of Verrica Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Verrica Pharmaceuticals: Ventyx Biosciences, Inc. (17.54%), Kamada Ltd. (0.12%), Organogenesis Holdings Inc. (10.76%), CorMedix Inc. (17.11%), Neoleukin Therapeutics, Inc. (0.35%), Vanda Pharmaceuticals Inc. (3.80%), Atea Pharmaceuticals, Inc. (2.37%), UroGen Pharma Ltd. (17.91%), Nkarta, Inc. (11.27%), Procaps Group S.A. (0.03%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Verrica Pharmaceuticals stock? Short selling VRCA is an investing strategy that aims to generate trading profit from Verrica Pharmaceuticals as its price is falling. VRCA shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Verrica Pharmaceuticals? A short squeeze for Verrica Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VRCA, which in turn drives the price of the stock up even further. How often is Verrica Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VRCA, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: VTYX Short Squeeze KMDA Short Squeeze ORGO Short Squeeze CRMD Short Squeeze NLTX Short Squeeze VNDA Short Squeeze AVIR Short Squeeze URGN Short Squeeze NKTX Short Squeeze PROC Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VRCA) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersProof that the Musk/Bezos rivalry is about to hit a new levelInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm PressGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaUrgent Nvidia WarningAltimetry